Ibuprofen and fatal lung cancer: A brief report of the prospective results from the Third National Health and Nutrition Examination Survey (NHANES III)
- Authors:
- Marisa A. Bittoni
- David P. Carbone
- Randall E. Harris
View Affiliations
Affiliations: Comprehensive Cancer Center, The Ohio State University, Columbus, OH 43210, USA
- Published online on: May 5, 2017 https://doi.org/10.3892/mco.2017.1239
-
Pages:
917-920
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
This article is mentioned in:
Abstract
Chronic inflammation appears to increase the risk of lung cancer and, reciprocally, agents that reduce inflammation have been found to reduce this risk. However, few prospective studies have assessed whether there exists an association between lung cancer and the use of non‑steroidal anti‑inflammatory drugs (NSAIDs). In the present study, the association between fatal lung cancer and NSAIDs was investigated using cohort data from the Third National Health and Nutrition Examination Study (NHANES III). Baseline data were collected on smoking, NSAID use and other lifestyle factors for 10,735 participants during 1988‑1994, with cause‑specific mortality status ascertained through probabilistic record matching based on the National Death Index until 2006. Cox proportional hazards regression models were conducted to estimate hazard ratios (HRs) and confidence intervals (CIs) for NSAID use and death from lung cancer, controlling for current smoking and other covariates. During the 18 years of follow‑up, 269 participants succumbed to lung cancer, of whom 252 (93.6%) reported a history of cigarette smoking. Since all but 17 of the 269 fatal lung cancer cases occurred among current or former smokers, estimates of NSAID effects were ascertained from a sub‑cohort of 5,882 individuals who reported a history of past or current cigarette smoking. Multivariate regression models revealed that regular use of ibuprofen resulted in a 48% reduced risk of lung cancer mortality (HR=0.52, 95% CI: 0.33‑0.82, P<0.01). The main effects of other compounds tested, such as aspirin or acetaminophen, were not statistically significant. Our results suggest that high‑risk subgroups of smokers may benefit from the regular use of specific NSAIDs, which may prove to be a useful strategy for lung cancer prevention.
View References
|
1
|
Ferlay J, Soerjomataram I, Ervik M,
Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and
Bray F: GLOBOCAN 2012 v1.0. Cancer Incidence and Mortality
Worldwide. IARC Cancer Base No. 11. International Agency for
Research on Cancer; Lyon, France: 2013
|
|
2
|
Harris RE: Epidemiology of Lung
CancerHarris RE: Global Epidemiology of Cancer. Jones &
Bartlett Learning; Burlington, MA: pp. 39–58. 2016
|
|
3
|
Harris RE: Ibuprofen in the prevention and
therapy of cancerIbuprofen, Discovery, Development and
Therapeutics. Rainsford KD: John Wiley & Sons; West Sussex: pp.
518–546. 2015
|
|
4
|
Khuder SA, Herial NA, Mutgi AB and
Federman DJ: Nonsteroidal anti-inflammatory drug use and lung
cancer: A meta-analysis. Chest. 127:748–754. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
National Center for Health Statistics, .
Plan and operation of the Third National Health and Nutrition
Examination Survey, 1988–94. Vital and Health Statistics I.
32:1–416. 1994.
|
|
6
|
U.S. Department of Health and Human
Services, . Third National Health and Nutrition Examination Survey,
NHANES III Examination Data File. Public Use Data File
Documentation Number 76200. Hyattsville, MD: Centers for Disease
Control and Prevention; 1996
|
|
7
|
National Center for Health Statistics, .
Office of Analysis and Epidemiology, The Third National Health and
Nutrition Examination Survey (NHANES III) Linked Mortality File,
Mortality follow-up through. 2006. Matching Methodology;
Hyattsville, Maryland: 2009
|
|
8
|
Rainsford KD: Pharmacology and toxicology
of ibuprofenIbuprofen, Discovery, Development and Therapeutics.
Rainsford KD: John Wiley & Sons; West Sussex: pp. 132–236.
2015
|
|
9
|
Herschman HR: Regulation of prostaglandin
synthase-1 and prostaglandin synthase-2. Cancer and Metas Rev.
13:241–256. 1994. View Article : Google Scholar
|
|
10
|
Balkwill F and Mantovani A: Inflammation
and cancer: Back to Virchow? Lancet. 357:539–545. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Coussens LM and Werb Z: Inflammation and
cancer. Nature. 420:860–867. 2000. View Article : Google Scholar
|
|
12
|
Harris RE: Cyclooxygenase-2 (cox-2) and
the inflammogenesis of cancer. Subcell Biochem. 42:93–126. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shiff SJ and Rigas B: The role of
cyclooxygenase inhibition in the antineoplastic effects of
nonsteroidal anti-inflammatory drugs (NSAIDs). J Exp Med.
190:445–450. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Harris RE, Beebe-Donk J and Alshafie GA:
Cancer chemoprevention by cyclooxygenase2 (COX-2) blockade: Results
of case control studies. Subcell Biochem. 42:193–212. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Olsen JH, Friis S, Poulsen AH, Fryzek J,
Harving H, Tjønneland A, Sørensen HT and Blot W: Use of NSAIDS,
smoking and lung cancer risk. Br J Cancer. 98:232–237. 2008.
View Article : Google Scholar : PubMed/NCBI
|
